ProPhase Labs, Inc. Secured Debt
ProPhase Labs, Inc. (PRPH) had Secured Debt of $0 as of 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:SecuredDebt · last filed 2023-03-29
- 2022-12-31: Secured Debt $0.00.
- 2021-12-31: Secured Debt $0.00.
- 2016-03-31: Secured Debt $1.47M.
- 2015-12-31: Secured Debt $1.47M.
| Period end | Secured Debt |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-29 |
| 2021-12-31 | $0.00 10-Q · filed 2022-11-10 |
| 2016-03-31 | $1.47M 10-Q · filed 2016-05-13 |
| 2015-12-31 | $1.47M 10-K · filed 2017-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |